Race Oncology launches new corporate strategy designed to maximise the value of bisantrene

[ad_1] Race Oncology Ltd (ASX:RAC) has launched a new corporate strategy focused on maximising bisantrene’s anti-cancer and cardio-protective potential. The company’s lead clinical focus will be on investigating anti-cancer, plus…